Saturday, November 6, 2021

Genentech, Novartis get FDA nod for self-injectable Xolair


The FDA has approved a self-injectable form of Genentech and Novartis’ Xolair. Introducing the new prefilled syringe product will free patients from the need to visit healthcare providers to get treated. 

Novartis, which co-promotes Xolair with Genentech in the U.S., won approval for a self-administered version of Xolair in the European Union in 2018. As the pandemic ramped up around one year ago, Marie-France Tschudin, president of Novartis Pharmaceuticals, told investors that home delivery of Xolair was “being accelerated across different markets.”

The FDA approval positions Novartis and Genentech to expand self-administration of Xolair to the U.S. Novartis said the option is “particularly timely given the COVID-19 pandemic” and Kenneth Mendez, CEO and president, Asthma and Allergy Foundation of America, welcomed the approval.

“The possibility of administering FDA-approved treatment outside of the healthcare provider’s office, but still guided by that healthcare provider, may reduce barriers to care for patients and their caregivers,” Mendez said in a statement.

Certain limitations apply to the self-injection option. Given the risk of anaphylaxis, self-injection is restricted to patients without a history of severe allergic reactions. Patients that are permitted to self-inject need to administer at least three doses under close observation of a healthcare provider with no allergic reactions.

The approval for self-injection covers all authorized indications for Xolair, including allergic asthma, and continues Novartis’ ongoing effort to expand and improve on the original version that won approval in 2003. Xolair originally came to market as a powder in a vial for reconstitution. The FDA approved a pre-filled syringe version in 2018.

While working to improve administration of Xolair, the U.S. syringe formulation patents for which expire in 2021 and 2025, Novartis has also been advancing a potential successor to the drug. Two phase 3 trials are comparing a next-generation monoclonal anti-immunoglobulin E antibody, ligelizumab, to Xolair in chronic spontaneous urticaria. Data are due this year.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...